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ORIGINAL ARTICLE
Evidence for the role of EPHX2 gene variants in anorexia nervosa
AA Scott-Van Zeeland1,2, CS Bloss1,2, R Tewhey2,3, V Bansal1,2, A Torkamani1,2,3, O Libiger1,3, V Duvvuri4, N Wineinger1,2,
L Galvez1, BF Darst1,2, EN Smith4, A Carson1,2, P Pham1,2, T Phillips1,2, N Villarasa1,2, R Tisch1,2, G Zhang1,2, S Levy1,2,3,
S Murray1,2,3, W Chen5, S Srinivasan5, G Berenson5, H Brandt6, S Crawford6, S Crow7, MM Fichter8, KA Halmi9, C Johnson10,
AS Kaplan11,12,13, M La Via14, JE Mitchell15,16, M Strober17, A Rotondo18, J Treasure19, DB Woodside12,13,20, CM Bulik14,21, P Keel20,
KL Klump22, L Lilenfeld23, K Plotnicov24, EJ Topol1,2,3, PB Shih4, P Magistretti25, AW Bergen26, W Berrettini27, W Kaye4 and NJ Schork1,2,3
Anorexia nervosa (AN) and related eating disorders are complex, multifactorial neuropsychiatric conditions with likely rare and
common genetic and environmental determinants. To identify genetic variants associated with AN, we pursued a series of
sequencing and genotyping studies focusing on the coding regions and upstream sequence of 152 candidate genes in a total of
1205 AN cases and 1948 controls. We identified individual variant associations in the Estrogen Receptor- (ESR2) gene, as well as a
set of rare and common variants in the Epoxide Hydrolase 2 (EPHX2) gene, in an initial sequencing study of 261 early-onset severe
AN cases and 73 controls (P¼ 0.0004). The association of EPHX2 variants was further delineated in: (1) a pooling-based replication
study involving an additional 500 AN patients and 500 controls (replication set P¼ 0.00000016); (2) single-locus studies in a cohort
of 386 previously genotyped broadly defined AN cases and 295 female population controls from the Bogalusa Heart Study (BHS)
and a cohort of 58 individuals with self-reported eating disturbances and 851 controls (combined smallest single locus Po0.01). As
EPHX2 is known to influence cholesterol metabolism, and AN is often associated with elevated cholesterol levels, we also
investigated the association of EPHX2 variants and longitudinal body mass index (BMI) and cholesterol in BHS female and male
subjects (N¼ 229) and found evidence for a modifying effect of a subset of variants on the relationship between cholesterol and
BMI (Po0.01). These findings suggest a novel association of gene variants within EPHX2 to susceptibility to AN and provide a
foundation for future study of this important yet poorly understood condition.
Molecular Psychiatry (2014) 19, 724–732; doi:10.1038/mp.2013.91; published online 3 September 2013
Keywords: anorexia nervosa; EPHX2; genomics; hyperlipidemia; pooling; sequencing
INTRODUCTION
A multitude of environmental, behavioral and genetic factors have
been shown to be associated with anorexia nervosa (AN) and AN
predisposition.1,2 However, although AN and its psychological
correlates have been shown to be quite heritable (for example,
46–78%;3–6) and have a very high sibling recurrence risk (B10-
fold;7,8), candidate gene and genome-wide searches for common
single nucleotide variants (SNVs) and copy number variants (CNVs)
that influence AN susceptibility have not yielded statistically
compelling and replicable findings to date9–11 except possibly in
the case of AN recovery.12
Research focused on the discovery of genes and genetic variants
associated with common neuropsychiatric conditions has been
greatly aided by the rapid development of genetic technologies,
including efficient high-throughput genotyping, CNV detection and
next-generation sequencing. For example, recent applications of
high-throughput genetic assays have identified unequivocal
associations involving rare CNVs with autism and related develop-
mental disorders,13,14 as well as schizophrenia.15–18 However, no
genetic studies of other common neuropsychiatric conditions have
identified strong associations with either more frequent CNVs or
other more abundant forms of genetic variation, such as SNVs and
small insertion-deletion variants (indels). This may be attributable to
a number of factors including the following: (1) the fact that
neuropsychiatric diseases are oligogenic or polygenic in nature,
making it difficult to identify each and every variant contributing to
the diseases through single-locus analyses; (2) complex diseases
such as AN may be influenced by collections of rare SNVs
and indels—in addition to more common variant effects—which
are hard to detect without large sample sizes, next-generation
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sequencing technologies and sophisticated data analytic
strategies; and (3) in the absence of deep phenotyping, the
broad AN diagnosis may include a very heterogeneous set of
patients with unique genetic profiles, confounding the detection of
any one gene or set of genes. In light of these issues, the
identification of groups of rare variants that collectively contribute
to AN that may affect different physiologic pathways or mechan-
isms will thus require well-characterized and -phenotyped patients,
large sample sizes, sophisticated DNA-sequencing strategies or all
of these.
We exploited a multistage, large-scale sequencing strategy
interrogating the coding regions and neighboring sequence of
152 candidate genes hypothesized to be involved in feeding
behaviors, dopamine function, GABA and serotonin signaling, as
well as previously identified candidate genes and regions from
genome-wide association studies, including OPRD1, CHD9 and
EPHX2 (Epoxide Hydrolase 2),9,12,19,20 to identify genetic variants
that contribute to AN. We carried out the sequencing on an initial
Discovery cohort (261 AN cases; 73 controls) and a DNA-pooling-
based Replication cohort (500 AN cases and 500 controls) to
identify associations involving both individual SNVs and indels, as
well as collections of rare SNVs and indels, that are associated with
AN. In this way, we sought to identify variants that are not likely to
be detectable with the current genome-wide association study
(GWAS) strategies that focus on a select number of common SNVs
that explain some of the heritable components of AN and
neuropsychiatric disorders in general.21–23 We further replicated a
subset of the associated variants arising from the two sequencing
studies in an additional set of previously genotyped AN and eating
disordered (ED) cases (N¼ 444) and controls (N¼ 1146) using
imputation-based methods. Finally, we assessed the impact of
these variants on the longitudinal body mass index (BMI) and
cholesterol profiles of participants in the Bogalusa Heart Study
(BHS),24 tested for association between EPHX2 variants and
relevant psychometric variables, and considered the expression
profiles of the associated genes in the human brain via the Allen
Brain Atlas.25,26
MATERIALS AND METHODS
Samples
We used DNA samples from 262 individuals diagnosed with AN and 80
controls with extensive phenotype information from the Price Foundation
(PF) sample repository for the initial sequencing study.9 We initially
selected a sample of 300 women, self-reported Caucasian, with a
clinically diagnosed history of Restricting-type Anorexia or Restricting-
type with Purging Anorexia (average age of symptom onset 14 years;
see Supplementary Table 1), a lifetime BMI of 15 or less and an assessment
age of 19 years or greater as an evidence that they had a chronic
disease course (65% of selected patients reported symptoms within
the previous 12 months). Women with a history of regular binging
behaviors were initially excluded (bulimia nervosa, binge ED and
so on), with the aim of creating a more homogeneous sample to increase
power for gene discovery. A total of 100 control women with no history of
AN who also had current BMI measures between 18 and 29 were
selected and matched by age, self-reported ethnicity and study enroll-
ment site. Individuals with AN and controls had been previously
phenotyped on a wide variety of psychometric scales, including the
Temperament and Character Inventory;27 Beck Depression Inventory
(BDI),28 State-Trait Anxiety Inventory;29 Yale-Brown-Cornell Eating
Disorders Scale;30 and Structured Inventory of Anorexia Nervosa and
Bulimic Syndromes.31 Of the 300 women with AN and 100 control women,
262 AN cases and 80 controls had sufficient high-quality DNA for
sequencing. We also used DNA samples from 500 individuals with AN
and 500 controls from the PF repository that were independent of
the 262 AN and 80 control women used in the initial sequencing
study. In addition, we took advantage of additional cohorts for replication
studies, leveraging an independent set of AN cases from a previous GWAS
of PF AN cases.9 Figure 1 provides a schematic detailing the samples and
analyses.
Ancestry assessment
In order to determine the ancestry of the individuals from the PF repository
to be used in the sequencing studies, we exploited a database of 1115
individuals with known ancestries from 11 global populations for whom
genotype data are available from the third phase of the International
HapMap Project.32 We used multidimensional scaling analyses on the
genotype data with the PF samples along with the individuals with
known ancestry. Only individuals who exhibited clear clustering with
individuals of European descent were included in the sequencing analysis.
In the Discovery stage, one case was excluded because of evidence of
cryptic admixture with a Hispanic population, and in the Imputation-based
cohort replication, one BHS female and six control females from the
Scripps Genomic Health Initiative (SGHI) were excluded because of cryptic
admixture.
Target capture
We used the solution-based hybridization target capture technology
developed by Agilent33 to target B775 kilobases (kb) of unique DNA
sequences covering the exons plus 1 kb upstream from exon 1 for 152
candidate genes involved in feeding behaviors, dopamine, GABA and
serotonin signaling, as well as previously identified candidate genes and
regions.9,12,19 Supplementary Table 5 lists all the genes that we studied.
Initial study sequencing and variant calling procedures
After the target capture assays, we performed sequencing with the
Illumina GAIIX using indexing across four runs with 12 barcodes per lane.
We sequenced all 262 cases and 80 controls. Average coverage for each
individual for the targeted regions was 125X, with at least 10X coverage
for 93.4% of the targeted regions. To call variants from the sequence
data, reads were first aligned to the Human Genome Reference (HG18)
using the BFAST alignment program,34 and the variants were called using
CRISP with the default parameters35 for all targeted regions plus 100
flanking base pairs.
Quality controls
Quality-control steps included exclusion of individuals with greater than
10% missing genotype calls (seven Discovery-stage controls), and
exclusion of variants with greater than 10% missing genotype calls and
Hardy–Weinberg equilibrium test Po10 4. To assess the quality of the
variant calls, we included technical control samples (HuRef) on multiple
sequencing runs and comparing genotype assignments at the loci for
which genotype information was available from a previous sequencing
study.36 These comparisons indicated a high level of fidelity in our
sequencing and variant calling pipelines. We achieved concordance of
95.85% with Sanger sequencing data for the HuRef technical control. Our
average between-run concordance for 15 technical replicate samples
(inclusive of HuRef) sequenced on multiple runs was 93%. A significant
fraction of discordant variants across samples was indels.
Pooling-based replication study sequencing and variant calling
procedures
We used the pooling-based sequencing protocol and analysis strategy
outlined by Bansal et al.37 We created 50 total pools, each containing DNA
from 20 individuals (25 pools with DNA from 20 AN subjects and 25 pools
with DNA from 20 control subjects). In addition, we constructed one pool
made up of individuals who had been sequenced previously in the
Discovery phase. This allowed us to compare allele frequencies derived
from the sequencing of the pool against allele frequencies based on
genotype counts from the individual genotype data (see Supplementary
Materials) to test the fidelity of the pooling and sequencing processes.
A total of 2087 variants were called in this pool. A total of 4 variants were
excluded as tri-allelic, 57 variants were missed when compared with the
previous genotype information, 17 were called with no support for
alternate allele and 15 were from one individual. Allele frequencies
estimated from the pooled sequencing for the remaining genotypes
showed a very strong correlation with the previously determined
genotype-based allele frequencies on the basis of explicit genotype
counting (overall R2¼ 0.988; Supplementary Figure 2). The equimolar pools
were sequenced on the Illumina HiSeq. Each pool of AN subjects was
sequenced to B908X coverage, or B45X per individual in the pool and
each pool of control subjects was sequenced to B895X per pool, or 45X
per individual. Reads from the pools were aligned to the human reference
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genome with the program BWA38 and variant calling was performed with
the program CRISP.35 After quality control, 4798 variants remained for
further analysis.
Variant annotations
All variants passing quality-control filters were annotated using a suite of
computational and bioinformatics techniques including Polyphen239 and
SIFT.40 In addition, identified variants were compared with variants in single
nucleotide polymorphism database41 and the 1000 Genomes Database42 to
determine their novelty. The results of the functional annotations were used
to inform the association analyses as described below.
Statistical analysis in the initial sequencing study
Variants passing quality filters were tested for association with AN using
simple single-locus analyses based on the regression model-based tests in
the software package PLINK.43 In addition, a ridge regression-based
collapsed set association test was used to test the hypothesis that
collections of variants, informed by likely functionally significant
annotations, distinguish AN patients from controls.44,45 Although we did
pursue other collapsed set analyses, ridge regression-based tests were
chosen as the primary analysis methods because of their flexibility in
accommodating covariates, their ability to accommodate correlations
between predictors attributable to, for example, linkage disequilibrium,
their ability to accommodate weighting, and their ability to simultaneously
assess common variant effects, individual rare variant effects and collapsed
sets of rare variant effects.44,45 A total of 2380 sets made up of collections
of rare variants included variants in each exon that were likely damaging to
the encoded protein based on Polyphen2 score,39 variants in each exon,
variants in each gene and variants in known complexes of genes and
pathways. To obtain an accurate estimate of the P-value for the set-based
tests, 10 000 permutations of AN/control status were generated, the test
was recomputed and the frequency with which a permutation-based test
resulted in a value more outlying than the original test statistic was
recorded to establish an empirical P-value.
Statistical analysis in the pooled DNA-replication study
Variants passing quality-control measures were tested for frequency
differences between the pools composed of DNA from AN patients and
pools composed of DNA from controls. Allele frequency estimates were
obtained by summing DNA-sequencing reads harboring the variant and
dividing by the total number of DNA-sequencing reads across the pools
mapping to a genomic location covering the variant position. Single-locus
tests for frequency differences were pursued with Fisher’s exact test. Set-
based tests using the same set derived in the initial sequencing study
analysis were conducted by computing the collective frequency of the
variants estimated from the sequencing reads in the AN and control pools
and comparing these frequencies with Fisher’s exact test after transform-
ing the read counts for the two alleles at each variant to allele counts.37
Imputation-based replication cohorts
For replication, we exploited two previously genotyped groups of cases
obtained from different GWAS studies, one that focused on AN specifically
(referred to as the ‘GWAS’ cases9) and one with self-reported ED histories
assessed in the context of a study evaluating the impact of learning about
disease risk with genetic information (referred to as the SGHI subjects46).
We then compared genotypes among these cases with two sets of control
DISCOVERY
AssociationAnnotation
Quality Control
261 cases & 73 matched controls
6 sequencing controls 763 indels
262 cases & 80 matched controls
6 sequencing controls
152 genes :    7,836 SNVs
1,033 indels
8,121 single locus tests2,380 set-based tests
POOLED REPLICATION
20 Pools of 25 Samples for 
500 Cases & 500 Controls
152 genes
Association
4,798 single locus tests
Annotation
2,380 set-based tests
ADDITIONAL SINGLE-LOCUS REPLICATION OF EPXH2
444 Cases
1,146 Controls
EPHX2 & CHOLESTEROL
Association with Cholesterol 
profiles in BHS: 
295 Females & 229 Males
AN SUBPHENOTYPE
Beck Depression Inventory & 
Trait Anxiety in Discovery AN
152 genes : 7,358 SNVs
Figure 1. Diagrammatic representation of the study design and workflow for the initial and replication sequencing studies including the
number of variants identified and analyzed at each stage. In the Discovery phase, 262 cases with anorexia nervosa (AN) and 80 matched
controls were selected for sequencing. Exons and upstream promoter regions for 152 candidate genes were captured for targeted
sequencing. A total of 8121 variants were tested for association with AN using both single-locus tests and set-based methods (2380 sets).
Independent replication was pursued in 500 AN cases and 500 controls in the same set of 152 candidate genes (4798 variants; 2380 sets).
Additional study cohorts from previous genome-wide association studies (GWAS) were used in a second independent replication analysis
among 444 cases and 1146 controls and subphenotype-association tests.
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individuals having comparable ancestral backgrounds (that is, European)
based on genotype profile. One set was derived from the Bogalusa Heart
Study24 and one derived from the SGHI.46 This comparison included
genotyped as well as imputed markers based on 1000 Genomes Phase-I-
integrated variant set reference haplotypes. We used IMPUTE2 software
v2.2.2 (software provided by the Department of Statistics, Oxford
University) to impute a subset of associated variants arising from the
sequencing studies in these subjects.47,48 We used an information
threshold of 0.5. For samples that were sequenced and had prior GWAS
data, we performed the same imputation to assess concordance for the
imputed SNPs. For 128 samples on which we had sequencing and GWAS
data, the concordance between sequence-based genotypes and GWAS or
imputation-based genotypes for SNPs within EPHX2 was 97.7%. The AN
cases used for this second replication had extensive psychometric
profiling, and secondary analyses of these phenotypes were pursued.
Longitudinal analyses
As a further set of replications and to explore the phenotypic impact of
variants identified from our sequencing studies as associated with AN, we
assessed associations between these variants and longitudinal data on BMI
and other metabolic phenotypes (for example, cholesterol levels) in the
BHS data.24 The analyses were pursued to investigate the impact of
associated variants on the relationship between weight gain (that is,
change in BMI over time) and changes in total cholesterol level. A linear
mixed model that considered total cholesterol level as the dependent
variable and age, degree of European ancestry, BMI, genotype and a BMI
 genotype interaction term as independent variables was used for these
analyses. Separate analyses for male and female subjects were pursued.
Brain gene-expression analysis
We leveraged the Allen Brain Atlas to explore the expression patterns of
genes found to be associated with AN from our sequencing studies.25,26
Data for this analysis included EPHX2 expression data from three different
donors (H0351.2001, H0351.1009 and H0351.2002) represented by two
probes. Ten regions in which both the EPHX2 probes had an absolute
Z-score of X2.5 and were consistent across more than one donor were
noted as over/under expressing the gene. Five of the 13 brain regions are
biologically relevant structures and are highlighted in Supplementary
Table 4.
RESULTS
Initial sample characteristics
Sample sizes for each stage of data analysis are shown in Table 1,
and Supplementary Table 1 further provides information on
the phenotypic and clinical characteristics of these individuals.
As expected, the Discovery and Replication AN cases are
significantly different from the controls with respect to current
and previous BMI, anxiety levels and other measures of
psychological health (Supplementary Table 1).
Ancestry determination
Multidimensional Scaling analysis with individuals of known
ancestries was used to assess homogeneity of our initial sample
based on genotype information (see Materials and Methods).
Supplementary Figure 1 depicts the multidimensional Scaling
results, after excluding one AN individual who demonstrated
evidence of admixture, and indicates that the final sample of AN
case and control subjects for the Discovery-stage sequencing study
cluster with individuals of known European ancestry, suggesting
that there is little potential for population stratification and genetic
background heterogeneity to influence the association analyses.
Initial sequencing association analysis results
After quality control (see Materials and methods), 7358 SNVs and
763 indels remained for further analysis. We performed single-
locus-based association analyses using the logistic regression test
implemented in the genetic analysis software package PLINK.43 No
single variant reached genome-wide significance (Po10 8). The
two variants with the lowest P-values resided in the Estrogen
Receptor Beta gene (ESR2; 7.1 10 4) and had been previously
observed and reported in single nucleotide polymorphism
database41 (as rs1256066 and rs944050). We also pursued
collapsed set variant analyses using ridge regression methods as
described in the Materials and Methods section.44,45 A total of
2380 collapsed variant sets were tested for association.
Supplementary Table 2 provides a ranked list (by P-value from
the ridge regression analysis) of the top collapsed sets of variants
that fall within the targeted exon regions, the nearest gene and
the nature of the collapsing used to define the set (that is, all
variants within a targeted exon, predicted functional variants
within a region, predicted functional variants within a gene
category and so on). The top two sets comprised 35 variants in
ITPR3 and 14 variants in EPHX2.
Pooling-based replication analysis results
All variants arising from the pooling-based replication sequencing
study were subjected to single-locus and set-based allele
frequency difference tests between AN and control pools (see
Materials and methods). Of the top ranked sets from the
Discovery-stage analysis, only one set of variants in the EPHX2
gene was significantly associated in the pooling-based replication
study and thus suggested replication. Eight of the 14 variants
initially observed in the EPHX2 gene set (chr8:27456902–
27458639) at the Discovery stage were identified in the same
set in the Replication stage and are denoted by an asterisk (*) in
Table 2. The columns labeled ‘Pools’ in Table 3 provide the
frequencies for the EPHX2 gene variants within the replicated set
in the pooled replication cohort. We also found evidence for
additional replication of the ESR2 gene variants in our other
cohorts of previously studied (GWAS) AN cases and self-reported
(SGHI) ED women, consistent with the previous evidence for a role
for estrogen in AN49,50 and prior association with this gene.20 Note
that sets of variants identified in the initial sequencing were tested
for association in the pooling-based replication study using
combined frequency estimates of the variants defining the sets.
In addition, in conducting these tests, only variants that were
present in the replication sequencing data were used to form the
set (for example, some variants identified in the initial sequencing
Table 1. Summary of study cohorts
Sample N
Price foundation phase 1
Cases 261
Controls 73
Price foundation phase 2
Cases 500
Controls 500
Price foundation GWAS
Cases 386
Scripps Genomic Health Initiative
Cases 58
Controls 851
Bogalusa Heart Study
Controls—female 295
Controls—male 229
Total cases 1205
Total controls 1948
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study—especially novel variants—were not identified in
the replication sequencing study). It can be seen from
Supplementary Table 2 that a set of variants in the EPHX2 gene
exhibited association in both the initial (14 variant sets; ridge
regression P¼ 0.0004) and the replication (8 variant sets; Fisher’s
exact test adjusted P-value after control for multiple comparisons
via 10 000 permutations ¼ 0.0062) sequencing studies. The EPHX2
gene variants in the set included coding and non-coding variants
with the variants that replicated residing primarily in a linkage
disequilibrium block that covers the last three exons of the gene,
including part of the 3’-untranslated region (UTR) (Table 2).
Imputation-based single-locus replication
To further test the association between AN and ESR2 and EPHX2
gene variants, we imputed the subset of EPHX2 and ESR2 variants
that were implicated from the previous analysis stages in the AN
GWAS, BHS and SGHI replication cohorts (see Materials and
methods). There was some evidence of association with AN status
at the single-locus level via a combined analysis, as indicated in
Table 3. To further characterize the impact of the associated EPHX2
gene variants, we investigated associations with these variants
with measures of depression and anxiety collected on the
Discovery AN cases (N¼ 261) (see Supplementary Table 3).
Table 4 provides the results of these analyses and suggests that
these variants may exhibit association with AN-relevant psycho-
metric traits of Trait Anxiety (TA) and Depression (BDI). Interest-
ingly, we observed an association not only between variants in
EPHX2 and BDI and TA but also a significant interaction between
EPHX2 gene variants and BMI and BDI scores. As shown in
Supplementary Figure 4, women with AN who carry AN-associated
EPHX2 variants (rs1126452, rs1042032 and rs1042064) show
increasing BDI depression scores with decreasing BMI. No BMI
SNP interaction models for TA were significant, and thus only the
main effects are reported.
Longitudinal analyses
Given that the EPHX2 gene is known to influence cholesterol
function (as discussed in greater depth in the Discussion), we
considered the influence of the subset of associated variants that
could be imputed in the BHS data set on longitudinal BMI and
cholesterol levels. We found evidence that one EPHX2 gene
variant, rs2291635, had an impact on the relationship between
weight gain (that is, increase in BMI over time) and cholesterol
profile measures (total cholesterol, triglycerides, high-density
Table 2. Significant EPHX2 variants from exon-based set test, discovery and replication
Replication Chr Position VarType Ref Alt Location Coding impact rsID
EPHX2 8 27454730 snp G A Intron_15/14 — rs59039594
* 8 27457059 snp G A Intron_16/15 — rs2291635
8 27457077 del ACA — Intron_16/15 — —
* 8 27457179 snp C T Intron_16/15 — —
8 27457194 snp G A Exon_17/16 Synonymous —
8 27457304 snp G A Intron_17/16 — —
8 27457623 snp C A Exon_18/17 Nonsynonymous —
* 8 27457709 snp G T Intron_18/17 — —
* 8 27457881 snp A C Exon_19/18 Synonymous rs1126452
* 8 27457991 snp A G 3UTR — rs1042032
* 8 27458049 snp T C 3UTR — rs1042064
* 8 27458411 snp C T Downstream — rs4149259
* 8 27458470 snp A G Downstream — —
8 27458512 snp G A Downstream — —
8 27458581 snp G A Downstream — —
Abbreviation: EPHX2, Epoxide Hydrolase 2.
Table 3. Single-locus minor allele frequencies for all cohorts
Cases Controls
Gene Chr Position rsID Discovery Pools GWAS SGHI Discovery Pools BHS SGHI Pools P Combined P
EPHX2 8 27457059 rs2291635 0.0785 0.0859 0.0925 0.0603 0.1319 0.1061 0.1058 0.1122 7.45E-02 9.18E-03
8 27457179 — 0.0019 0.001 NA NA 0 0 NA NA NA NA
8 27457709 — 0 0 NA NA 0.0068 0.002 NA NA NA NA
8 27457881 rs1126452 0.228 0.1967 0.2487 0.2456 0.274 0.2473 0.3034 0.2581 5.03E-03 7.70E-03
8 27457991 rs1042032 0.228 0.1962 0.2487 0.2456 0.2708 0.2445 0.3034 0.2578 6.67E-02 6.20E-02
8 27458049 rs1042064 0.228 0.2021 0.2552 0.2411 0.2945 0.2514 0.3102 0.2579 2.38E-02 1.59E-02
8 27458411 rs4149259 0.1494 0.1201 0.1554 0.1842 0.137 0.16 0.1932 0.1410 5.93E-03 9.11E-02
8 27458470 rs189089713 0.0019 0 0 0 0 0.001 0 0 NA NA
ESR2 14 63768644 rs1256066 0.0383 0.0294 0.04275 0.0175 0.1096 0.0412 0.0356 0.0294 9.02E-02 1.44E-03
14 63769798 rs944050 0.0383 0.0318 0.04275 0.0175 0.1096 0.0454 0.0373 0.0294 8.14E-02 1.54E-03
14 63793804 rs1256049 0.0383 0.0274 0.04036 0.0259 0.1027 0.0425 0.0339 0.0287 3.36E-02 1.43E-03
Abbreviations: BHS, Bogalusa Heart Study; EPHX2, Epoxide Hydrolase 2; ESR, Estrogen Receptor-; GWAS, genome-wide association study.
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lipoprotein cholesterol and low-density lipoprotein cholesterol)
based on an interaction model (see Materials and methods and
Table 5) among both female (Figure 2) and, interestingly, male
subjects from the BHS study. No other EPHX2 gene variants
showed significant association with cholesterol profiles.
Gene-expression analysis
Given that EPHX2 has been implicated primarily in cholesterol
metabolism with documented expression in tissues such as liver
and kidney,51 we performed a post hoc exploration of EPHX2 gene
expression using publically available data from a recent meta-
analysis by Liang and colleagues (2013)52 and the Allen Brain Atlas
(see Materials and methods). Data from a recent exploration of
14 177 expression quantitative trait loci (eQTL) accessed at
www.hsph.harvard.edu/liming-liang/software/eqtl/ reveal that
one of the replicated SNPs from our study, rs4149259, acts as an
eQTL for gene expression of EPHX2 (P¼ 5.17E-20). Significant
EPXH2 gene-expression patterns identified from the Allen Brain
Atlas are provided in Supplementary Table 4 and suggest that the
EPHX2 gene is expressed in neural tissues of relevance to feeding
behaviors, anxiety and other AN-associated phenomena. Namely,
elevated expression of EPHX2 observed in the paraventricular
nucleus (PVN) of the thalamus is interesting in light of studies
linking PVN function to food and water intake,53 weight gain in
rats54 and stress response.55 Additionally, abnormal expression in
sexually dimorphic regions such as the corpus callosum and the
hippocampus may also indicate a sex-specific effect of EPHX2 in
the manifestation of AN. Finally, high levels of EPHX2 expression
were noted in the subcallosal gyrus, which has been implicated in
depression and is functionally connected to the thalamus and
limbic system.56
DISCUSSION
AN is likely influenced by complex interactions between genetic
variants, environmental and social factors. Whereas some genetic
variants that contribute to these interactions are likely common,
results of the only GWAS analyses to date did not show strong
associations between common variants and AN,9 although it was
limited by small sample size. We therefore leveraged DNA-
sequencing studies in a multistage design to identify and replicate
both common and rare variants in biologically relevant AN
candidate genes that would not necessarily have been found in
common variant-based candidate gene and GWAS analyses. Our
initial sequencing study focused on a well-characterized cohort of
261 early-onset AN-affected individuals (mean 14 years) and 73
controls followed by a pooling-based replication study involving a
much larger set of (n¼ 500) AN cases and (n¼ 500) controls
(mean onset 16 years). We searched for both single-locus
associations and collapsed rare variant set-based associations in
Table 4. EPHX2 psychometric subphenotype analysis in AN
BDI main effecta BDI BMI SNPa
Trait anxiety
main effectb
Variant b P b P b P
rs2291635 0.266 0.458  0.162 0.650 0.131 0.030*
rs1126452 1.280 0.002**  1.180 0.004** 0.125 0.039*
rs1042032 1.280 0.002**  1.180 0.004** 0.125 0.039*
rs1042064 1.280 0.002**  1.180 0.004** 0.125 0.039*
rs4149259 1.156 0.005  1.115 0.007 0.046 0.449
Abbreviations: BDI, Beck Depression Inventory; EPHX2, Epoxide Hydrolase 2.
*Po0.05; **Po0.005; aN¼ 257; bN¼ 254.
Table 5. EPHX2 rs2291635 associations with cholesterol profile
Females Males
BMI SNP BMI SNP BMI SNP BMI SNP
b P b P b P b P b P b P
Total Cholesterol 1.03 8.5 10-12 12.69 0.045* -0.636 0.009** 1.22 1.43 10-8  13.28 0.107 0.577 0.044*
Triglycerides 3.36 4.15 10-33 20.06 0.068  1.11 0.014* 5.80 5.90 10-28  20.31 0.290 0.920 0.208
HDL Cholesterol  0.054 3.08 10-10 7.39 0.031*  0.188 0.179  0.97 7.60 10-19 4.42 0.273  0.228 0.138
LDL Cholesterol 0.946 4.18 10-12 0.750 0.896  0.204 0.352 1.31 2.62 10-12  15.13 0.034 0.650 0.009**
Abbreviations: BMI, body mass index; EPHX2, Epoxide Hydrolase 2; HDL, high-density lipoprotein; LDP, low-density lipoprotein; SNP, single-nucleotide length
polymorphism.
*Po0.05; **Po0.01.
Figure 2. Scatter plot depicting the relationship between long-
itudinal BMI trajectories against longitudinal total cholesterol
trajectories as a function of rs2291635 genotype for Bogalusa
female subjects. Points in red represent the common homozygote
genotype and those in blue represents the heterozygote. The rare
homozygote is omitted.
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both initial and replication stages. We found some evidence that
ESR2 may harbor variants associated with AN, which is interesting
in light of the fact that AN is observed in female subjects to a
much higher degree than in male subjects, and given its typical
onset in adolescence.57 This finding is also consistent with
previous studies suggesting that estrogen and estrogen
receptors may have a role in mediating the disease.49,58
Importantly, we found more statistically compelling evidence
for set-based associations involving a collection of rare variants in
the EPHX2 gene and were able to replicate a subset of these
variants in additional case cohorts and controls. EPHX2 was
included in the gene list for targeted sequencing because of its
presence in a list of top associated genes from a preliminary
GWAS analysis.9 Still, the role of EPHX2 in AN was not obvious, so
we explored potential links between EPHX2 function and AN. The
EPHX2 gene is expressed in vascular and non-vascular neural
tissues of relevance to AN and is known to influence cholesterol
function,51,59 suggesting multiple potential roles in the etiology or
maintenance of AN. Interestingly, it has been well documented
that a substantial proportion of malnourished individuals with AN
have high serum cholesterol,60 and this may be due to genetic
variation.61 In fact, the EPHX2 gene variants were also found to be
associated with total cholesterol levels measured on one of our
replication cohorts (BHS) as well as comorbid symptoms that are
common in AN for a large proportion of our study subjects.
The EPHX2 gene codes for the soluble epoxide hydrolase (sEH)
protein, which is widely expressed in a variety of tissues, including
the liver, lungs, kidney, heart, brain, adrenals, spleen, intestines,
urinary bladder, placenta, skin, mammary gland, testis, leukocytes,
vascular endothelium and smooth muscle but is most highly
expressed in the liver and kidney.51,62,63 sEH catalyzes the
hydrolysis of epoxides to their corresponding diols, easily
metabolizes both saturated and unsaturated epoxy fatty acids
and is highly conserved with nearly all functioning polymorphisms
having been defined.51 The specific activity of sEH varies 500-fold
in the human liver, suggesting a wide range of potential
regulatory mechanisms,64 and sEH gene transcription may also
be induced by sex hormones and regulated by the hypothalamic–
pituitary–gonadal axis.51 Through its complex epoxide hydrolysis
of epoxy eicosatrienoic acids (EETs) into diols (DHETs), sEH reduces
the number of EETs ready for release by phospholipases and may
stop the biological activity of these lipids.62 Together, they
influence the regulation of inflammation, blood pressure, lipid
and carbohydrate metabolism.51
Relevant to this study are previous animal studies that reveal a
dynamic change in sEH activity in response to diet. Mice fed high-
carbohydrate high-fat (HCHF) diets show typical sequelae of
metabolic syndrome, including increased body weight, abdominal
fat and plasma lipid abnormalities, among others. In these obese
animals, sEH activity in liver was 18% higher than mice fed a
standard diet.65 However, when rats fed a HCHF diet were given
an sEH inhibitor, metabolic, liver and cardiovascular abnormalities
were attenuated, suggesting a direct role for sEH in the etiology of
dyslipidemia in response to diet. Total sEH activity was also found
to be higher in adipose tissue of rats fed a HCHF diet.66 These
studies, together with the findings of this study, may suggest a
role for EPHX2 and the gene product sEH in lipid regulation in
response to diet.
The observation that AN patients often display hypercholestero-
lemia in addition to their condition is counterintuitive, given the
under-nutrition and low body weight of affected individuals.
Fortunately, recovery from anorexia nearly always leads to
recovery from hypercholesterolemia, even in very severe cases.67
It has been hypothesized that low levels of cholesterol may
decrease the activity of serotonin receptors and transporters and
that significantly lower cholesterol levels are associated with
depressive symptoms, impulsive/self-harmful behavior (cutting
and/or burning) and suicide thoughts/attempts in anorexia
patients.67 Moreover, lower cholesterol levels have been
associated with increased suicidality more broadly, including
ideation and attempts, in depressed patients.68 Notably, from this
research, it has been suggested that among depressed patients,
BMI and total cholesterol had a negative correlation, and patients
with higher cholesterol levels were observed to be significantly
less depressed, impulsive and suicidal. We found evidence that a
subset of EPHX2 gene variants associated with AN also influence
the relationship between increases in BMI and total cholesterol.
These data may suggest a role for EPHX2 gene variants in
mediating AN-associated physiological changes consistent with
previous studies showing an association between genetic variants
within EPHX2 and association with lipid profiles and cardiovascular
disease.69,70
The observed association between AN and variants in EPHX2 is
particularly interesting in light of the EPHX2 gene-expression
pattern observed in the brain. Data from the Allen Brain Atlas
indicate EPHX2 enrichment in tissues associated with feeding
behaviors, depression and stress response, including the para-
ventricular nucleus and subcallosal gyrus. Although our investiga-
tion of EPHX2 gene expression in the brain in this study was
exploratory, future studies leveraging functional or structural brain
imaging may clarify neural correlates of EPHX2 genetic variants
and contribution to AN-related phenotypes. For example, previous
neuroimaging genetic studies have identified associations
between genetic variants in the serotonin transporter, anxiety
and neural tissues of relevance such as amygdala and cingulate,71
and correlated CNTNAP2 gene-expression patterns in brain to
frontostriatal functional connectivity patterns associated with
variants in the CNTNAP2 gene.72
It will be important to verify the significance of the variants we
have identified in a number of ways.73 First, replication of the
variants we have identified in larger data sets is crucial. Second,
identifying additional phenotypes that may be influenced by the
variants we found to be associated with AN would help put in
perspective the physiological and neural pathways these genetic
variants influence to impact AN susceptibility. For example, it
would be interesting to evaluate associations between
cholesterol-related phenotypes and the EPHX2 gene in a sample
of individuals with AN. Third, it would be important to assess the
functional significance of the variants in order to characterize the
molecular pathways that they influence, specifically whether they
are associated with lower basal sEH activity. Fourth, imaging-
genetics studies that evaluate possible links between EPHX2 and
structural and functional measures of the brain regions implicated
in AN may provide further insight into the relationship between
this gene and AN susceptibility. Taken together, our study
represents the largest sequencing study of AN to date, and we
hope that it will set the stage for further work into this debilitating
and life-threatening disease.
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